Ersoy, B. Et Al. 2018. Asymmetric dimethylarginine levels and diabetes duration: Relationship with measures of subclinical atherosclerosis and cardiac function in children and adolescents with Type 1 diabetes. DIABETES & VASCULAR DISEASE RESEARCH , vol.15, no.3 , 196-203.

Ersoy, B., Eroglu, N., Cetin, M., Onur, E., Ozkol, M., & Coskun, S., (2018). Asymmetric dimethylarginine levels and diabetes duration: Relationship with measures of subclinical atherosclerosis and cardiac function in children and adolescents with Type 1 diabetes. DIABETES & VASCULAR DISEASE RESEARCH , vol.15, no.3, 196-203.

Ersoy, Betul Et Al. "Asymmetric dimethylarginine levels and diabetes duration: Relationship with measures of subclinical atherosclerosis and cardiac function in children and adolescents with Type 1 diabetes," DIABETES & VASCULAR DISEASE RESEARCH , vol.15, no.3, 196-203, 2018

Ersoy, Betul Et Al. "Asymmetric dimethylarginine levels and diabetes duration: Relationship with measures of subclinical atherosclerosis and cardiac function in children and adolescents with Type 1 diabetes." DIABETES & VASCULAR DISEASE RESEARCH , vol.15, no.3, pp.196-203, 2018

Ersoy, B. Et Al. (2018) . "Asymmetric dimethylarginine levels and diabetes duration: Relationship with measures of subclinical atherosclerosis and cardiac function in children and adolescents with Type 1 diabetes." DIABETES & VASCULAR DISEASE RESEARCH , vol.15, no.3, pp.196-203.

@article{article, author={Betul Ersoy Et Al. }, title={Asymmetric dimethylarginine levels and diabetes duration: Relationship with measures of subclinical atherosclerosis and cardiac function in children and adolescents with Type 1 diabetes}, journal={DIABETES & VASCULAR DISEASE RESEARCH}, year=2018, pages={196-203} }